Results of flow cytometry and histologic analysis indicated that combination therapy boosted the numbers of activated CD8+ T cells at both injected and uninjected sites, inferring that an expansion of tumor-reactive CD8+ T cells occurred locally and systemically (Figure 4C,D). The gene discussed is CD8A; the disease is neoplasm.